Summary
Definition
History and exam
Key diagnostic factors
- family history of pattern hair loss
- gradual receding and thinning of frontal hairline, central scalp, and crown (vertex)
- diffuse thinning of the central scalp with preservation of frontal and temporal hairline
Risk factors
- family history of pattern hair loss
- advancing age
- polycystic ovary syndrome in women
- metabolic syndrome
- exogenous androgen intake
Diagnostic tests
1st tests to order
- hair-pull test
Tests to consider
- CBC with differential
- thyroid function tests
- serum ferritin
- comprehensive metabolic panel
- antinuclear antibodies
- rapid plasma reagin
- free testosterone
- serum dehydroepiandrosterone (DHEA)-sulfate
- sex hormone-binding globulin
- androstenedione
- 17-alpha hydroxyprogesterone
- estradiol
- LH
- follicle-stimulating hormone (FSH)
- dermatoscopy/trichoscopy
- scalp biopsy
Treatment algorithm
men who opt for conservative management
men who opt for medical management
women who opt for conservative management
women who opt for medical management
unsatisfactory response to medical treatment
Contributors
Authors
Carolyn Goh, MD
Associate Clinical Professor
Department of Medicine
Division of Dermatology
UCLA Medical Center
Los Angeles, CA
Disclosures
CG has served as a consultant for Veradermics, Pfizer, AbbVie, and Arcutis. She has been on an advisory board for Veradermics and is on the speakers bureau for Pfizer and Sun Pharma. She is an investigator with CorEvitas.
Acknowledgements
Dr Carolyn Goh would like to gratefully acknowledge Dr Robert Haber, Dr Christiane Querfeld, and Dr Christopher R. Shea, previous contributors to this topic.
Disclosures
RH has an ownership interest in a company that manufactures light-based hair growth devices and receives royalties for the sales of a surgical device used in hair restoration surgery. CQ and CRS declare that they have no competing interests.
Peer reviewers
Jennifer Fu, MD
Director Hair Disorders Clinic
Department of Dermatology
University of California
San Francisco, CA
Disclosures
JF declares that she has consulted for Eli Lilly, Pfizer, and Sun Pharmaceuticals. She is an editor for DynaMed on related topics.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
European Dermatology Forum. S3 - European Dermatology Forum guideline for the treatment of androgenetic alopecia in women and in men. 2017 [internet publication].Full text
Carmina E, Azziz R, Bergfeld W, et al. Female pattern hair loss and androgen excess: a report from the multidisciplinary androgen excess and PCOS committee. J Clin Endocrinol Metab. 2019 Jul 1;104(7):2875-91. Abstract
Elhassan YS, Hawley JM, Cussen L, et al. Society for Endocrinology clinical practice guideline for the evaluation of androgen excess in women. Clin Endocrinol (Oxf). 2025 Oct;103(4):540-66.Full text Abstract
Goodman NF, Bledsoe MB, Cobin RH, et al. American Association of Clinical Endocrinologists medical guidelines for the clinical practice for the diagnosis and treatment of hyperandrogenic disorders. Endocr Pract. 2001 Mar-Apr;7(2):120-34.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Differentials
- Diffuse alopecia areata
- Acute telogen effluvium
- Chronic telogen effluvium
More DifferentialsGuidelines
- Society for Endocrinology clinical practice guideline for the evaluation of androgen excess in women
- Female pattern hair loss and androgen excess: a report from the multidisciplinary Androgen Excess and PCOS Committee
More GuidelinesLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer